Currently, BridgeBio Pharma Inc [BBIO] is trading at $32.31, down -0.86%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BBIO shares have gain 0.25% over the last week, with a monthly amount glided 3.82%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On September 04, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $46 on the stock. BMO Capital Markets initiated its recommendation with a Market Perform and recommended $37 as its price target on January 31, 2024. Wells Fargo started tracking with a Overweight rating for this stock on December 08, 2023, and assigned it a price target of $58. In a note dated December 08, 2023, Wells Fargo initiated an Overweight rating.
This stock has fluctuated between a low of $21.62 and a high of $39.47 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $45.5 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $32.31 at the most recent close of the market. An investor can expect a potential return of 40.82% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
Trailing Twelve Months sales for BridgeBio Pharma Inc [NASDAQ:BBIO] were 221.90M which represents 237.08% growth. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -2.66%, Pretax Profit Margin comes in at -2.44%, and Net Profit Margin reading is -2.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.58, Equity is 0.44 and Total Capital is -0.67. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 31.83 points at the first support level, and at 31.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 32.80, and for the 2nd resistance point, it is at 33.30.
Ratios To Look Out For
To put it in perspective, the Current Ratio for BridgeBio Pharma Inc [NASDAQ:BBIO] is 4.67. As well, the Quick Ratio is 4.67, while the Cash Ratio is 16.48. Considering the valuation of this stock, the price to sales ratio is 27.69.
Transactions by insiders
Recent insider trading involved Valantine Hannah, Director, that happened on Mar 06 ’25 when 12875.0 shares were sold. 10% Owner, KKR Genetic Disorder L.P. completed a deal on Mar 05 ’25 to sell 6.0 million shares. Meanwhile, Director HANNAH A VALANTINE bought 12875.0 shares on Mar 06 ’25.
